Decision on PGR: Feb 25, 2020
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
FINAL WRITTEN DECISION
|
PGR2018-00092
|
08/21/2018
|
02/25/2019
|
Grunenthal GmbH
|
9,820,999
|
Antecip Bioventures II LLC
|
Some Challenged Claims Unpatentable
|
US 9,820,999 (ANTECIP BIOVENTURES II LLC; Exp: May 15, 2034): Non-OB
1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising selecting a human being having CRPS triggered by bone fracture and administering neridronic acid or a pharmaceutically acceptable salt thereof to the human being, wherein the treatment is effective in reducing pain.
Asserted Grounds of Unpatentability:
Claims
|
35 U.S.C.
|
Reference(s)/Basis
|
1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29
|
102(a)
|
Varenna 2012
|
1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29
|
102(a)
|
Varenna 2016
|
1–4, 9, 10, 12, 14, 16–18, 24–25, 27–29
|
102(a)
|
Manara
|
1–4, 9–20, 22–29
|
103(a)
|
Varenna 2012, Varenna 2016, Manara, Bruehl
Gatti, La Montagna, and
Muratore
|
5–8, 21
|
103(a)
|
Varenna 2012, Varenna 2016,
Manara, and Manicourt
|
30
|
103(a)
|
Varenna 2012, Varenna 2016
Manara, Schwarzer, Bruehl,
Gatti, La Montagna, and Muratore
|
1–30
|
112(a),
Enablement
|
Order:
It is ORDERED that claims 1–4, 9, 10, 12, 14, 16–18, 23–25, and 27–29 of the ’999 patent are unpatentable;
FURTHER ORDERED that claims 5–8, 11, 13, 15, 19–22, 26, and 30 of the ’999 patent are not shown to be unpatentable.
Leave a Reply